AIRR - ANZCA Institutional Research Repository
Skip navigation
Please use this identifier to cite or link to this item: https://hdl.handle.net/11055/589
Title: Patient Preference for Sustained-Release versus Standard Paracetamol (Acetaminophen): A Multicentre, Randomized, Open-Label, Two-Way Crossover Study in Subjects with Knee Osteoarthritis
Authors: Benson M
Marangou A
Russo M 
Durocher J
Collaku A
Starkey YY
Keywords: paracetamol
Acetaminophen
knee
osteoarthritis
patient preference
compliance
Issue Date: 1-Oct-2009
Source: 37(5):1321-1335
Abstract: Guidelines for osteoarthritis (OA) management recommend paracetamol (acetaminophen) as the most appropriate first-line analgesic for mild to moderate pain. Standard paracetamol requires four times daily dosing. Drug compliance and convenience are inversely related to daily dose frequency. Compliance is a pivotal component of the successful management of OA pain and is influenced by patient preferences or beliefs. The added convenience of three times daily dosing may enhance compliance and, therefore, pain relief. This multicentre, randomized, open-label, two-way crossover, phase IV study is the first to evaluate patient preference with a sustained-release paracetamol tablet formulation designed for three times daily dosing. Compared with standard paracetamol tablets dosed four times daily, the sustained-release formulation was preferred in a 2:1 ratio, provided better overall joint pain relief, resulted in higher levels of satisfaction in subjects with OA of the knee and has the potential to improve patient compliance and, therefore, pain control.
URI: http://hdl.handle.net/11055/589
Appears in Collections:Scholarly and Clinical

Files in This Item:
File Description SizeFormat 
Patient Preference for Sustained-Release versus Standard Paracetamol - Knee OA (ID 65295).pdf
  Restricted Access
182.3 kBAdobe PDFView/Open    Request a copy
Show full item record

Page view(s)

48
checked on Mar 28, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.